摘要
目的 观察奥曲肽联合恩替卡韦对乙型肝炎相关晚期肝癌的临床疗效和安全性.方法 选择2012年6月-2014年12月在我院住院的乙型肝炎相关晚期肝癌患者90例,分为奥曲肽联合恩替卡韦治疗组（A组22例）,奥曲肽治疗组（B组23例）,恩替卡韦治疗组（C组21例）和单纯内科保肝组（D组24例）.随访监测治疗后4、12、24及48W肝功能、AFP、HBV-DNA定量、腹部彩色超声或CT,每4W对患者生活质量包括食欲、体重及乏力等情况进行现场或电话随访,所有患者随访4-48 W.结果 奥曲肽联合恩替卡韦治疗组,奥曲肽治疗组,恩替卡韦治疗组生活质量较常规治疗组改善,生存时间延长,其中奥曲肽联合恩替卡韦治疗组最明显,其次为奥曲肽治疗组与抗病毒治疗组,常规治疗组无改善,P〈0.05,差异具有统计学意义.结论 奥曲肽联合恩替卡韦治疗乙型肝炎相关晚期肝癌可提高生活质量、延长生存时间,提高生存率等,且不良反应轻.
Objective Observation the clinical efficacy and safety of OCT combinewith ETV on patients with hepatitis B virus-related advanced hepatocellular carcinoma.Methods Selected 90 patients with hepatitis B virus-related advanced hepatocellular carcinoma hospitalized from June 2012 to December 2014 in our hospital, were randomly divided into the OCT combined with ETV group （ group A, n=22 ）, OCT group （ group B, n=23 ）, ETV group （ group C, n=21） and pure medical liver protection group （ group D, n=24）. Liver function, AFP, HBV-DNA, abdominal color ultrasound or CT were quantified at 4, 12, 24, 48 weeks. The patient＇s appetite, weight and lack of power were followed up by on-site or telephone. All patients were followed up from 4 weeks to 48 weeks.Results Compared with the routine treatment group, quality of life and survival time of patients in OCT combined with ETV group, OCT group and ETV group improved. Among them, those of patients in OCT combined with ETV group were the most obvious, followed with OCT group and ETV group. Routine treatment group showed no improvement,P〈0.05, had difference statistically signiifcance.Conclusion OCT combined with ETV with less adverse reaction can improve the quality of life and survival rate and prolong the survival time to patients with hepatitis B virus-related advanced hepatocellular carcinoma.
出处
《中国继续医学教育》
2015年第23期153-155,共3页
China Continuing Medical Education
